Valuation: Pulmonx Corporation

Market Cap 79.45M 70.92M 65.91M 59.96M 113M 7.53B 115M 792M 310M 3.93B 298M 292M 12.56B P/E 2026 *
-1.77x
P/E 2027 * -1.96x
Enterprise Value 79.45M 70.92M 65.91M 59.96M 113M 7.53B 115M 792M 310M 3.93B 298M 292M 12.56B EV / Sales 2026 *
0.88x
EV / Sales 2027 * 0.81x
Free-Float
95.36%
Yield 2026 *
-
Yield 2027 * -
1 day+3.93%
1 week+2.21%
Current month-3.14%
1 month-3.14%
3 months+28.47%
6 months+23.33%
Current year-16.29%
1 week 1.72
Extreme 1.72
1.93
1 month 1.72
Extreme 1.72
2.09
Current year 1.13
Extreme 1.13
2.59
1 year 1.13
Extreme 1.13
2.89
3 years 1.13
Extreme 1.13
14.84
5 years 1.13
Extreme 1.13
45.49
10 years 1.13
Extreme 1.13
69.48
Manager TitleAgeSince
Chief Executive Officer 64 26/10/2025
Director of Finance/CFO 53 30/04/2019
Chief Tech/Sci/R&D Officer 52 31/01/2020
Director TitleAgeSince
Director/Board Member 72 31/01/2007
Chairman 66 30/09/2019
Director/Board Member 64 17/12/2014
Date Insider Type Main position Quantity % Market Cap. Importance
01/09/26 Sell

Chief Technology Officer

-14,245 0.0332%
01/09/26 Sell

Chief Executive Officer

-41,882 0.0975%
01/09/26 Sell

Executive/Senior Manager

-7,879 0.0183%
Change 5-day change 1-year change 3-year change Capi.($)
+3.93%+2.21%+14.91%-76.85% 76.45M
+2.29%+6.28%-19.13%+15.20% 178B
+1.29%+8.77%+0.12%+32.64% 121B
+4.12%+5.87%-20.70%+13.71% 108B
+0.41%+3.99%-44.97%-9.38% 75.7B
+1.56%+6.24%+6.82%+80.66% 64.15B
+1.58%+1.16%+14.55%+66.63% 53.49B
+2.58%+6.02%+3.74%-25.10% 51.45B
+3.43%+6.63%-14.39%+28.39% 41.68B
+5.08%+3.91%+34.09%+15.12% 31.5B
Average +2.62%+5.07%-2.50%+14.10% 72.48B
Weighted average by Cap. +2.29%+5.88%-9.87%+22.78%

Financials

2026 *2027 *
Net sales 90.55M 80.82M 75.12M 68.33M 129M 8.58B 131M 902M 353M 4.47B 340M 333M 14.32B 98.31M 87.76M 81.56M 74.19M 140M 9.31B 142M 980M 383M 4.86B 369M 361M 15.55B
Net income -44.24M -39.48M -36.7M -33.38M -62.8M -4.19B -63.93M -441M -172M -2.19B -166M -162M -7B -40.71M -36.34M -33.78M -30.72M -57.8M -3.86B -58.84M -406M -159M -2.01B -153M -150M -6.44B
Net Debt - -
Projected Income Statement - Annual - Pulmonx Corporation
Logo Pulmonx Corporation
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.
Employees
296
Date Price Change Volume
15/10/26 US$1.850 +3.93% 268,114
14/10/26 US$1.780 +1.14% 285,309
13/10/26 US$1.760 -2.22% 498,611
12/10/26 US$1.800 -2.17% 428,718
09/10/26 US$1.840 +1.66% 204,437
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Pulmonx Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.850USD
Average target price
3.400USD
Spread / Average Target
+83.78%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Pulmonx Corporation
  1. Stock Market
  2. Stocks
  3. LUNG Stock